FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug

Core Insights - Roche's new drug application (NDA) for giredestrant has been accepted by the FDA, targeting treatment for ER-positive, HER2-negative, ESR1-mutated breast cancer, with a decision expected by December 18, 2026 [1][7]. Drug Development and Efficacy - Giredestrant, in combination with everolimus, could become the first oral selective estrogen receptor degrader (SERD) combination available post-CDK4/6 inhibitor approval if successful [2]. - The phase III evERA study demonstrated that the giredestrant/everolimus combination significantly improved progression-free survival (PFS), reducing the risk of disease progression or death by 44% in the overall population and 62% in ESR1-mutated patients [5][7]. - Median PFS was extended to 8.77 months in the intention-to-treat (ITT) group and 9.99 months in the ESR1-mutated population, compared to 5.49 and 5.45 months in the control arm [6]. Market Performance - Over the past year, Roche's shares have increased by 43%, outperforming the industry growth of 12.1% [4]. Future Plans - Roche is advancing giredestrant through five phase III studies across multiple treatment settings, with additional data from the lidERA study expected to be submitted to global health authorities soon [8][9]. - The successful development of giredestrant is anticipated to enhance Roche's breast cancer franchise, as ER-positive breast cancer accounts for approximately 70% of diagnosed cases [10].